MX378733B - Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus. - Google Patents
Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus.Info
- Publication number
- MX378733B MX378733B MX2018000448A MX2018000448A MX378733B MX 378733 B MX378733 B MX 378733B MX 2018000448 A MX2018000448 A MX 2018000448A MX 2018000448 A MX2018000448 A MX 2018000448A MX 378733 B MX378733 B MX 378733B
- Authority
- MX
- Mexico
- Prior art keywords
- lupus
- identifying
- compositions
- treatment
- vitro methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6858—Allele-specific amplification
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q99/00—Subject matter not provided for in other groups of this subclass
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2533/00—Reactions characterised by the enzymatic reaction principle used
- C12Q2533/10—Reactions characterised by the enzymatic reaction principle used the purpose being to increase the length of an oligonucleotide strand
- C12Q2533/101—Primer extension
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Animal Behavior & Ethology (AREA)
- Theoretical Computer Science (AREA)
- Plant Pathology (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93915607P | 2007-05-21 | 2007-05-21 | |
| US1328307P | 2007-12-12 | 2007-12-12 | |
| PCT/US2008/064430 WO2008144761A2 (en) | 2007-05-21 | 2008-05-21 | Methods and compositions for identifying and treating lupus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX378733B true MX378733B (es) | 2025-03-10 |
Family
ID=40122294
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010728A MX353428B (es) | 2007-05-21 | 2008-05-21 | Métodos y composiciones para identificar y tratar lupus. |
| MX2018000448A MX378733B (es) | 2007-05-21 | 2008-05-21 | Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus. |
| MX2009012531A MX343167B (es) | 2007-05-21 | 2008-05-21 | Metodos y composiciones para identificar y tratar lupus. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010728A MX353428B (es) | 2007-05-21 | 2008-05-21 | Métodos y composiciones para identificar y tratar lupus. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009012531A MX343167B (es) | 2007-05-21 | 2008-05-21 | Metodos y composiciones para identificar y tratar lupus. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20110046094A1 (enExample) |
| EP (3) | EP2158335A2 (enExample) |
| JP (4) | JP5728226B2 (enExample) |
| KR (4) | KR20190015629A (enExample) |
| CN (3) | CN103298950B (enExample) |
| AU (1) | AU2008254582A1 (enExample) |
| BR (1) | BRPI0811930B8 (enExample) |
| CA (1) | CA2690608C (enExample) |
| ES (1) | ES2661249T3 (enExample) |
| HK (1) | HK1255086A1 (enExample) |
| IL (1) | IL201949A0 (enExample) |
| MX (3) | MX353428B (enExample) |
| RU (1) | RU2009147281A (enExample) |
| WO (1) | WO2008144761A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103298950B (zh) * | 2007-05-21 | 2015-01-21 | 健泰科生物技术公司 | 用于鉴定和治疗狼疮的方法和组合物 |
| MX2011003273A (es) * | 2008-09-26 | 2011-04-28 | Genentech Inc | Metodo para tratar, diagnosticar y supervisar lupus. |
| US20100105061A1 (en) * | 2008-10-29 | 2010-04-29 | University Of Southern California | Autoimmune genes identified in systemic lupus erythematosus (sle) |
| EP2403959A1 (en) * | 2009-03-03 | 2012-01-11 | Merck Serono S.A. | Bank1 related snps and sle and/or ms susceptibility |
| EP3219813B1 (en) | 2009-10-07 | 2020-11-18 | H. Hoffnabb-La Roche Ag | Methods for diagnosing lupus |
| MX2012010116A (es) * | 2010-03-01 | 2013-02-26 | Alexion Pharma Inc | Metodos y composiciones para el tratamiento de la enfermedad de degos. |
| BR112013020498A2 (pt) * | 2011-02-10 | 2016-08-09 | Genqual Corp | método para determinar a capacidade de resposta a inibidores e para tratamento de um sujeito |
| US20130317006A1 (en) | 2012-05-24 | 2013-11-28 | Amy Yasko | Use of polymorphisms for identifying individuals at risk of developing autism |
| WO2015081052A1 (en) | 2013-11-27 | 2015-06-04 | Yasko Amy | Use of polymorphisms for identifying individuals at risk of developing autism |
| AU2016281776B2 (en) * | 2015-06-24 | 2019-09-05 | Oxford BioDynamics PLC | Detection processes using sites of chromosome interaction |
| CN110459312B (zh) * | 2018-05-07 | 2024-01-12 | 深圳华大生命科学研究院 | 类风湿性关节炎易感位点及其应用 |
| EP4076671A4 (en) * | 2019-12-18 | 2024-04-17 | The Children's Hospital Of Philadelphia | Novel druggable targets for the treatment of inflammatory diseases such as systemic lupus erythematosus (sle) and methods for diagnosis and treatment using the same |
| KR20240021336A (ko) | 2022-08-09 | 2024-02-19 | 심재홍 | 수액 채취장치의 냉각기 구조 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4683203A (en) | 1984-04-14 | 1987-07-28 | Redco N.V. | Immobilized enzymes, processes for preparing same, and use thereof |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| IE61148B1 (en) | 1988-03-10 | 1994-10-05 | Ici Plc | Method of detecting nucleotide sequences |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| US5474796A (en) * | 1991-09-04 | 1995-12-12 | Protogene Laboratories, Inc. | Method and apparatus for conducting an array of chemical reactions on a support surface |
| ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
| AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0912761A4 (en) | 1996-05-29 | 2004-06-09 | Cornell Res Foundation Inc | DETERMINATION OF DIFFERENCES IN THE NUCLEIC ACID SEQUENCE BY MEANS OF A COMBINATION OF LIGASE DETERMINATION AND POLYMERASE CHAIN REACTION |
| EP2314625B1 (en) | 1996-12-03 | 2014-05-07 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| AU2001265121A1 (en) | 2000-05-30 | 2001-12-11 | Applera Corporation | Methods for detecting target nucleic acids using coupled ligation and amplification |
| US6900016B1 (en) | 2000-09-08 | 2005-05-31 | Applera Corporation | Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof |
| NZ525336A (en) * | 2000-10-20 | 2006-03-31 | Expression Diagnostics Inc | Leukocyte expression profiling |
| US7205106B1 (en) | 2001-07-20 | 2007-04-17 | Roche Molecular Systems, Inc. | Association of polymorphisms in IL4-related genes with autoimmune disease |
| JP2003061677A (ja) * | 2001-08-28 | 2003-03-04 | Olympus Optical Co Ltd | 全身性エリテマトーデスの感受性遺伝子およびその使用 |
| US20030119004A1 (en) | 2001-12-05 | 2003-06-26 | Wenz H. Michael | Methods for quantitating nucleic acids using coupled ligation and amplification |
| US7022476B2 (en) * | 2002-02-26 | 2006-04-04 | New York Society For Ruptured And Crippled Maintaining The Hospital For Special Surgery | Human FcγRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof |
| IL163600A0 (en) * | 2002-03-01 | 2005-12-18 | Ravgen Inc | Methods for detection of genetic disorders |
| EP1608783A2 (en) | 2003-03-18 | 2005-12-28 | Applera Corporation | Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof |
| WO2005086872A2 (en) * | 2004-03-10 | 2005-09-22 | Celera, An Applera Corporation Business | Ptpn22 polymorphisms in diagnosis and therapy |
| EP1863927A2 (en) * | 2005-03-15 | 2007-12-12 | Ares Trading S.A. | Compositions and methods for treating and diagnosing inflammatory disorders |
| EP2327792B9 (en) | 2005-08-05 | 2013-12-18 | Genentech, Inc. | Methods and compositions for detecting auto-immune disorders |
| US20070269827A1 (en) * | 2006-05-18 | 2007-11-22 | Oklahoma Medical Research Foundation | Predicting and Diagnosing Patients With Autoimmune Disease |
| CN103298950B (zh) * | 2007-05-21 | 2015-01-21 | 健泰科生物技术公司 | 用于鉴定和治疗狼疮的方法和组合物 |
| MX2011003273A (es) * | 2008-09-26 | 2011-04-28 | Genentech Inc | Metodo para tratar, diagnosticar y supervisar lupus. |
-
2008
- 2008-05-21 CN CN200880025560.5A patent/CN103298950B/zh active Active
- 2008-05-21 RU RU2009147281/10A patent/RU2009147281A/ru unknown
- 2008-05-21 MX MX2016010728A patent/MX353428B/es unknown
- 2008-05-21 CA CA2690608A patent/CA2690608C/en active Active
- 2008-05-21 KR KR1020197003511A patent/KR20190015629A/ko not_active Withdrawn
- 2008-05-21 CN CN201810571366.2A patent/CN108753946A/zh active Pending
- 2008-05-21 AU AU2008254582A patent/AU2008254582A1/en not_active Abandoned
- 2008-05-21 MX MX2018000448A patent/MX378733B/es unknown
- 2008-05-21 US US12/600,248 patent/US20110046094A1/en not_active Abandoned
- 2008-05-21 MX MX2009012531A patent/MX343167B/es active IP Right Grant
- 2008-05-21 WO PCT/US2008/064430 patent/WO2008144761A2/en not_active Ceased
- 2008-05-21 EP EP08769569A patent/EP2158335A2/en not_active Withdrawn
- 2008-05-21 BR BRPI0811930A patent/BRPI0811930B8/pt active IP Right Grant
- 2008-05-21 ES ES12192837.8T patent/ES2661249T3/es active Active
- 2008-05-21 JP JP2010509537A patent/JP5728226B2/ja active Active
- 2008-05-21 KR KR1020097026436A patent/KR101651678B1/ko active Active
- 2008-05-21 KR KR1020157032728A patent/KR101729431B1/ko active Active
- 2008-05-21 EP EP17191337.9A patent/EP3318643A3/en not_active Withdrawn
- 2008-05-21 CN CN201410815214.4A patent/CN104593488B/zh active Active
- 2008-05-21 EP EP12192837.8A patent/EP2612924B1/en active Active
- 2008-05-21 KR KR1020177009940A patent/KR101947093B1/ko active Active
-
2009
- 2009-11-05 IL IL201949A patent/IL201949A0/en unknown
-
2015
- 2015-04-08 JP JP2015079282A patent/JP6080059B2/ja active Active
-
2016
- 2016-09-13 JP JP2016178303A patent/JP2017035088A/ja active Pending
-
2018
- 2018-03-19 JP JP2018050492A patent/JP2018126146A/ja active Pending
- 2018-11-07 HK HK18114216.9A patent/HK1255086A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX378733B (es) | Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus. | |
| ATE527385T1 (de) | Mit tumoren assoziierte genetische variationen | |
| CY1121899T1 (el) | Βοριουχα μικρομορια ως αντιφλεγμονωδεις παραγοντες | |
| MY180473A (en) | Imaging and evaluating embryos, oocytes, and stem cells | |
| WO2010062960A3 (en) | METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE | |
| PA8800801A1 (es) | Regimenes de inmunoterapia dependientes del estado apoe | |
| CL2010001483A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune. | |
| CL2008001682A1 (es) | Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos. | |
| MA50079A (fr) | Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire | |
| MX2020010947A (es) | Metodos de tratamiento de enfermedad de alzheimer. | |
| MX2019015159A (es) | Composiciones, metodos y usos para asistir en el diagnostico, pronostico y tratamiento de la fibrosis pulmonar idiopatica. | |
| BR112012009262A2 (pt) | ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo | |
| MX2009012722A (es) | Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama. | |
| CO6450665A2 (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan | |
| NZ591613A (en) | Polymorphic marker rs965513 for risk assessment of thyroid cancer | |
| EA201600085A1 (ru) | Набор для обнаружения соевого события syht0h2 | |
| MX2009010439A (es) | Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama. | |
| ATE535805T1 (de) | Verfahren zur erkennung von autoantikörpern zur diagnostizierung und charakterisierung von erkrankungen | |
| DK2002016T3 (da) | Fremgangsmåde til bestemmelse af kopital | |
| WO2012094580A3 (en) | Compounds that modulate oxidative stress | |
| BRPI0912927A2 (pt) | "método de detectar um tumor independente de vegf em um indivíduo e método de tratar um tumor independente de vegf em um indivíduo" | |
| BRPI0702163A (pt) | composições de toner e métodos | |
| ECSP099675A (es) | Compuestos heterocíclicos, composición y métodos de uso | |
| UY33856A (es) | ?gen y variaciones asociadas con el fenotipo bm1, marcadores moleculares y su uso?. | |
| ATE549638T1 (de) | 13c-mr-bildgebung oder spektroskopie von zelltod |